In-vitro activity of cefepime and seven other antimicrobial agents against 1518 non-fermentative Gram-negative bacilli collected from 48 Canadian health care facilities

Journal of Antimicrobial Chemotherapy

Volumn 44, Issue 4, 1999, Pages 545-548

  Blondeau, J M ^a,b,c   Laskowski, R ^a   Borsos, S ^a  

^a Saskatoon Health Region St Pauls Hospital   (Canada)

^b ROYAL UNIVERSITY HOSPITAL   (Canada)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM; TOBRAMYCIN;

ACINETOBACTER; ANTIBACTERIAL ACTIVITY; ARTICLE; CANADA; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA;

ANTI-BACTERIAL AGENTS; CANADA; CEPHALOSPORINS; GRAM-NEGATIVE BACTERIA; HUMANS; MICROBIAL SENSITIVITY TESTS;

EID: 0032858563     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/44.4.545     Document Type: Article

References (11)

1. Botzenhart, K. & Doring, G. (1993). Etiology and epidemiology of Pseudomonas aeruginosa. In Pseudomonas aeruginosa as an Opportunistic Pathogen (Camapa, M., Bendinell, M. & Friedman, H., Eds), pp. 1-18. Plenum Press, New York, NY.
2. Pollack, M. (1990). Pseudomonas aeruginosa. In Principles and Practices of Infectious Diseases, 3rd edn (Mandell, G. L., Douglas, R. G. & Bennett, J. E., Eds), pp. 1673-91. Churchill Livingston, New York, NY.
3. Clarke, A. M., Zemcov, S. J. & Wright, J. M. (1985). HR 810 and BMY-28142, two new cephalosporins with broad-spectrum activity: an in-vitro comparison with other β-lactam antibiotics. Journal of Antimicrobial Chemotherapy 15, 305-10.
4. Tsuji, A., Maniatis, A., Bertram, M. A. & Young, L. S. (1985). In-vitro activity of BMY-28142 in comparison with those of other β-lactam antimicrobial agents. Antimicrobial Agents and Chemotherapy 27, 515-9.
5. National Committee for Clinical Laboratory Standards. (1997). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Fourth Edition: Approved Standard M7-A4. NCCLS, Wayne, PA.
6. Chamberland, S., L'Ecuyer, J., Lessard, C., Bernier, M., Provencher, P., Bergeron, M. G. et al. (1992). Antibiotic susceptibility profiles of 941 Gram-negative bacteria isolated from septicemic patients throughout Canada. The Canadian Study Group. Clinical Infectious Diseases 15, 615-28.
7. Hoban, D. J. & Jones, R. N. (1995). Canadian ofloxacin susceptibility study: a comparative study from 18 medical centers. Canadian Ofloxacin Study Group. Chemotherapy 41, 34-8.
8. Hoban, D. J. & Jones, R. N. (1993). The North American component (USA, Canada) of an international comparative MIC trial monitoring ofloxacin resistance. Drugs 45, Suppl. 3, 167-9.
9. Blondeau, J. M., Yaschuk, Y., Smith, J. A., Noble, M. A., Kibsey, P., Horsman, G. B. et al. (1996). Canadian ciprofloxacin susceptibility study: comparative study from 15 medical centers. Antimicrobial Agents and Chemotherapy 40, 1729-32.
10. Forward, K. R., Low, D. E., Laverdiere, M., Rennie, R., Simor, A. E. & Franks, P. A. (1997). Study of the comparative activity of piperacillin/tazobactam with currently available antibiotics against 8206 aerobic isolates. Canadian Journal of Infectious Diseases 8, 147-53.
11. Scriver, S. R. & Low, D. E. (1995). Comparative activity of several antimicrobial agents against nosocomial Gram-negative rods isolated across Canada. Canadian Journal of Infectious Diseases 6, 76-82.